SPOTLIGHT: Study questions Medtronic stent

Ahead of next week's FDA panel review of Medtronic's new Endeavor stent, the agency released documents questioning its effectiveness; the company's stock dipped 2 percent on the news. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.